Therapeutic development and current uses of BCL-2 inhibition
- Author(s)
- Roberts, AW;
- Details
- Publication Year 2020-12-04,Volume 2020,Issue #1,Page 1-9
- Journal Title
- Hematology Am Soc Hematol Educ Program
- Publication Type
- Journal Article
- Abstract
- B-cell lymphoma 2 (BCL2) is a key protein regulator of apoptosis. It is variably highly expressed in many hematological malignancies, providing protection from cell death induced by oncogenic and external stresses. Venetoclax is the first selective BCL2 inhibitor, and the first of a new class of anticancer drug (BH3-mimetics) to be approved for routine clinical practice, currently in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). To help understand the potential and limitations of this therapy, this brief review will touch on the history of development of venetoclax, dissect its mechanism of action, and summarize critical evidence for its approved use in the management of patients with CLL and AML. It will also consider recent data on mechanisms of resistance and explore concepts pertinent to its future development based on key lessons learned to date.
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 33275682
- Link To PubMed Central Version
- http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7727569/
- Publisher's Version
- https://doi.org/10.1182/hematology.2020000154
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-02-01 12:08:29
Last Modified: 2021-02-25 08:55:05